Dr Reddy terminates Armis Biopharma's investigation license of DFA-02
Hyderabad: Dr. Reddy’s Laboratories Ltd. has announced the termination of the license granted to Armis Biopharma, Inc. (formerly known as CHD Bioscience, Inc.) for its investigational antibacterial product, DFA-02, for the prophylaxis of surgical site infections (SSIs).
As a result of the termination, Dr. Reddy's has regained worldwide rights to DFA-02 and is currently evaluating its options to take the program forward.
DFA-02 is a combination, broad-spectrum antibacterial in situ gel which is being investigated for the prophylaxis of SSIs as an adjunct to conventional preoperative antibiotic prophylaxis. DFA-02 has been studied in several phases 1 and 2 clinical studies and has demonstrated clinical efficacy in several key segments of patients who were at high risk for SSIs.
As a result of the termination, Dr. Reddy's has regained worldwide rights to DFA-02 and is currently evaluating its options to take the program forward.
DFA-02 is a combination, broad-spectrum antibacterial in situ gel which is being investigated for the prophylaxis of SSIs as an adjunct to conventional preoperative antibiotic prophylaxis. DFA-02 has been studied in several phases 1 and 2 clinical studies and has demonstrated clinical efficacy in several key segments of patients who were at high risk for SSIs.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd